Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Esperion (ESPR)
Don't Miss TipRanks' Half-Year Sale
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AbbVie (ABBV)
In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on AbbVie. The company's shares closed last Tuesday at $189.77.
According to TipRanks.com, Breen is a 2-star analyst with an average return of 3.3% and a 61.9% success rate. Breen covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Gilead Sciences, and Merck & Company.
AbbVie has an analyst consensus of Moderate Buy, with a price target consensus of $213.00, a 14.0% upside from current levels. In a report issued on July 1, Citi also maintained a Hold rating on the stock with a $205.00 price target.
Esperion (ESPR)
In a report released yesterday, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Esperion, with a price target of $16.00. The company's shares closed last Tuesday at $1.17.
According to TipRanks.com, Pantginis has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -18.9% and a 29.9% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Genenta Science SpA Sponsored ADR, Adlai Nortye Ltd. Sponsored ADR, and Bioline RX Ltd Sponsored ADR.
Esperion has an analyst consensus of Moderate Buy, with a price target consensus of $6.37.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
37 minutes ago
- Business Wire
Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) resulting from allegations that Telix may have issued materially misleading business information to the investing public. So What: If you purchased Telix securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. What to do next: To join the prospective class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@ for information on the class action. What is this about: On July 22, 2025, Telix disclosed receipt of a subpoena from the U.S. Securities and Exchange Commission, which was 'seeking various documents and information primarily relating to the Company's disclosures regarding the development of the Company's prostate cancer therapeutic candidates.' On this news, Telix's American Depositary Receipt ('ADR') price fell $1.70 per ADR, or 10.44%, to close at $14.58 per ADR on July 23, 2025. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Attorney Advertising. Prior results do not guarantee a similar outcome.
Associated Press
an hour ago
- Associated Press
AbbVie Completes Acquisition of Capstan Therapeutics
NORTH CHICAGO, Ill., Aug. 19, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Capstan Therapeutics. With the completion of the acquisition, Capstan is now a part of AbbVie. Capstan's lead asset CPTX2309, currently in Phase 1 for the treatment of B cell-mediated autoimmune diseases, is a tLNP that generates CD19-specific, CD8+ in vivo CAR-T cells. The CAR-T cells are designed to achieve rapid and deep B cell depletion with the aim of achieving durable, drug-free remission. This can be accomplished without the need for lymphodepleting chemotherapy, while also avoiding other challenges associated with conventional ex vivo CAR-T therapies. 'With the acquisition now complete, we are excited to work together with the talented team at Capstan to advance our mission of transforming patient care,' said Jonathon Sedgwick, Ph.D., senior vice president and global head of discovery research, AbbVie. 'The addition of CPTX2309 and Capstan's tLNP platform strengthens our ability to deliver new treatments aimed at resetting the immune system and enables application of Capstan's proprietary technology more broadly for in vivo programming of cells.' For additional background on the acquisition, please read the press release announcing the definitive agreement under which AbbVie will acquire Capstan here. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at Follow @abbvie on LinkedIn,Facebook, Instagram, X (formerly Twitter), and YouTube. Forward-Looking Statements Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words 'believe,' 'expect,' 'anticipate,' 'project' and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, 'Risk Factors,' of AbbVie's 2024 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. View original content to download multimedia: SOURCE AbbVie
Yahoo
2 hours ago
- Yahoo
Will NIO's Vehicle Deliveries Accelerate in Q3 After a Modest July?
NIO Inc. NIO delivered 21,017 vehicles in July 2025, down from 24,925 vehicles in June 2025. The deliveries comprised 12,675 units from premium smart EV brand NIO, 5,976 units from family-oriented smart EV brand ONVO and 2,366 units from small, smart high-end electric car brand FIREFLY. As of July 31, 2025, NIO's cumulative deliveries were 806,731 EV pioneer of China launched ONVO L90 on July 31, 2025, which is expected to boost the company's deliveries in the third quarter. It delivered more than 4,000 units of L90 within 10 days of its launch. Currently, NIO's ONVO manufacturing facility in Hefei, Anhui province, is running at full capacity to boost output and speed up deliveries. ONVO aims to deliver more than 10,000 L90 units in August. If NIO reaches this goal, the L90 will record the highest monthly sales of any NIO model to NIO also plans to roll out the FIREFLY brand to several European countries as well as several other countries in the third quarter. As a result, NIO's total deliveries in the third quarter are expected to boost further year over year despite registering a modest increase in July. NIO carries a Zacks Rank #3 (Hold) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. July Deliveries of NIO's Competitors XPeng Inc. XPEV set a new monthly record in July 2025, with 36,717 smart EV deliveries, up 229% year over year, marking its ninth straight month of surpassing 30,000 units. As of July 2025, XPEV's cumulative deliveries have exceeded 800,000. In mid-July, XPENG introduced the 2025 models of the G6 and G9 in Europe and revealed plans to launch the P7+ in the Auto Inc. LI reported deliveries of 30,731 vehicles in July 2025, down 39.7% year over year. By the end of July, the company's total cumulative deliveries had reached 1,368,541 units. On July 29, 2025, Li officially unveiled the Li i8, a six-seat battery-electric family SUV. NIO's Price Performance, Valuation and Estimates NIO has outperformed the Zacks Automotive-Foreign industry year to date. Its shares have gained 16.3% compared with the industry's growth of 3.7%. Image Source: Zacks Investment Research From a valuation standpoint, NIO appears relatively overvalued. The stock trades at a forward price-to-sales (P/S) ratio of 0.65, above the industry's 0.45. Image Source: Zacks Investment Research The Zacks Consensus Estimate for 2025 bottom-line loss has widened by a penny in the past 30 days, while for 2026, it has narrowed by 5 cents in the past seven days. Image Source: Zacks Investment Research Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report NIO Inc. (NIO) : Free Stock Analysis Report Li Auto Inc. Sponsored ADR (LI) : Free Stock Analysis Report XPeng Inc. Sponsored ADR (XPEV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
